The Clinical Usefulness of Serum Prostate Specific Antigen After Hormonal Therapy of Metastatic Prostate Cancer

Miller, J.; Ahmann, Frederick R.; Drach, George W.; Emerson, Scott S.; Bottaccini, Manfred R.

doi:10.1016/s0022-5347(17)37432-3

Cited by 161 publications

(66 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, the decrease of serum PSA after hormonal treatment appears to be an important prognostic factor. 14 The Spearman rank-correlation coef®-cient between the nadir-PSA value during treatment and the best subjective response con®rmed the anticipated relationship (0.66 for n 481).…”

Section: Discussionmentioning

confidence: 73%

Safety and efficacy of a non-steroidal anti-androgen, based on results of a post marketing surveillance of nilutamide

Schasfoort¹,

Beek

Newling

2001

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

The use, tolerability and ef®cacy of the non-steroidal anti-androgen nilutamide (Anandron 1 ) in daily clinical practice was investigated in this 5-y project. In total 725 patients were recruited from 27 Dutch centres. The investigated population was very heterogeneous and different therapeutic options were reported. We may conclude that in general good results have been obtained, especially in ®rst line combination therapy combined with luteinising hormone releasing hormone (LHRH) agonists. Patients with a good performance status at inclusion seem to bene®t more from nilutamide combination therapy. Prostate Cancer and Prostatic Diseases (2001) 4, 112±117.

show abstract

Section: Discussionmentioning

confidence: 73%

Safety and efficacy of a non-steroidal anti-androgen, based on results of a post marketing surveillance of nilutamide

Schasfoort¹,

Beek

Newling

2001

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…Although PSA is a sensitive marker of prostate-related diseases, its production depends on androgens, therefore possibly complicating its use in androgen suppression trials and advanced androgen-insensitive tumours (Leo et al, 1991;Miller et al, 1992). An alternative technique to detect the progression of different tumours relies on the detection of tissue polypeptide antigen (TPA) released by cycling cells during S-and G2 phase (Marino et al, 1992).…”

Section: Discussionmentioning

confidence: 99%

“…Monitoring of serum testosterone and prostate-specific antigen (PSA) has been used in experimental animal models and clinical studies for the determination of the androgen-free treatment period by defining the level of tumour regrowth. However, the expression of PSA is androgen dependent, and therefore this marker may not adequately reflect tumour mass during androgen withdrawal therapy (Miller et al, 1992).…”

mentioning

confidence: 99%

Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy

Theyer

Holub²,

Dürer³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

Summary The present study evaluated serial serum measurements of tissue polypeptide-specific antigen (TPS) in comparison with prostatespecific antigen (PSA) for assessment of tumour progression in patients with advanced prostate cancer receiving intermittent androgen suppression therapy (IAS). Twenty-three men were recruited into an IAS trial consisting of an initial 8 months of androgen suppression, followed by cycles of treatment cessation and resumption of therapy upon increases of PSA > 20 ng ml-' to prolong the hormone responsiveness of the tumour cells. Periods of androgen suppression resulted in reversible reduction in serum testosterone (< 1.8 nmol l-1) and PSA (< 4 ng ml-') and decreases in tumour volume (mean reduction for first cycle 24 ± 10%), indicating partial growth arrest and apoptotic regression of the tumours. In contrast to PSA values, non-specifically elevated TPS values were found in 8 of 23 patients. In 15 of 23 patients, TPS fell during periods of apoptotic tumour regression and increased simultaneously with testosterone and preceded the increases in PSA by 2 months during the period of treatment cessation. Although TPS represents a highly sensitive marker of tumour proliferation in this IAS clinical model of controlled tumour regression and regrowth, its low specificity compared with PSA limits its usefulness to monitoring of prostate cancer patients with proven absence of non-specific elevations of this marker.

show abstract

“…Even more difficult is the question of when to restart: above a PSA level of 10 ng/ml (Hybritech) or should a percentage serum PSA increase be considered? Conflicting reports have been published concerning a correlation between PSA decline and impact on time to progression and survival [20,22,24]. Besides, serum PSA levels can be influenced by different factors and changes in serum levels could be independent of tumor response [17].…”

Section: Discussionmentioning

confidence: 99%

Intermittent androgen deprivation in advanced prostate cancer

Reijke

1997

Urol. Res.

View full text Add to dashboard Cite

The Clinical Usefulness of Serum Prostate Specific Antigen After Hormonal Therapy of Metastatic Prostate Cancer

Cited by 161 publications

References 35 publications

Safety and efficacy of a non-steroidal anti-androgen, based on results of a post marketing surveillance of nilutamide

Safety and efficacy of a non-steroidal anti-androgen, based on results of a post marketing surveillance of nilutamide

Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy

Intermittent androgen deprivation in advanced prostate cancer

Contact Info

Product

Resources

About